BioSyent Signs Licensing and Supply Agreement
February 05 2008 - 5:45PM
Marketwired
MISSISSAUGA, ONTARIO (TSX VENTURE: RX) is pleased to announce
that it has signed an agreement with a pharmaceutical developer and
manufacturer for the licensing and supply of a new pharmaceutical
product. This new product will be marketed as a generic drug in
Canada. The product launch is subject to regulatory approval.
BioSyent continues to concentrate on its pharmaceutical strategy
to source products that have been successfully developed and proven
to be safe and effective; manage these products through the
regulatory process and product registration (approval); and once
approved, market these products in Canada. These pharmaceuticals
will compete in both the branded and generic market segments and
will not require further product development investment other than
regulatory costs.
BioSyent Inc. is a publicly traded specialty pharmaceutical
company whose wholly owned subsidiary, BioSyent Pharma Inc.,
sources, acquires or in-licences pharmaceutical products and
markets these products in Canada. Wholly owned BioSyent subsidiary
Hedley Technologies Ltd. operates the company's legacy business
marketing bio and health friendly non-chemical insecticides.
BioSyent common shares are listed for trading on the TSX Venture
Exchange (TSXV) under the symbol RX.
This press release may contain information or statements that
are forward-looking. The contents herein represent our judgment, as
at the release date, and are subject to risks and uncertainties
that may cause actual results or outcomes to be materially
different from the forward-looking information or statements.
Potential risks may include, but are not limited to, those
associated with clinical trials, product development, future
revenue, operations, profitability and obtaining regulatory
approvals.
The TSX Venture Exchange assumes no responsibility for the
accuracy of this release and neither approves nor disapproves of
same.
Contacts: BioSyent Inc. Rene C. Goehrum President and CEO (905)
206-0013 (905) 206-1413 (FAX) Email: rgoehrum@biosyent.com Website:
www.biosyent.com
Biosyent (TSXV:RX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Biosyent (TSXV:RX)
Historical Stock Chart
From Jul 2023 to Jul 2024